StockNews.AI
SANA
StockNews.AI
119 days

Sana Biotechnology, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before May 20, 2025 to Discuss Your Rights - SANA

1. Sana Biotechnology facing a class action lawsuit for securities fraud allegations. 2. Investors claim misrepresentation of funding capabilities and product candidate prospects. 3. Lawsuit period is from March 17, 2023, to November 4, 2024. 4. Sana may reduce funding for key products or discontinue them. 5. Investors can join the lawsuit without out-of-pocket costs.

4m saved
Insight
Article

FAQ

Why Very Bearish?

The lawsuit indicates potential financial instability and mismanagement, which historically leads to stock declines.

How important is it?

The class action lawsuit directly threatens investor confidence and financial stability of SANA.

Why Short Term?

Legal proceedings may provoke immediate investor panic and volatility, as seen in similar cases.

Related Companies

NEW YORK, April 22, 2025 /PRNewswire/ --

Levi & Korsinsky, LLP notifies investors in Sana Biotechnology, Inc. ("Sana Biotechnology, Inc." or the "Company") (NASDAQ: SANA) of a class action securities lawsuit.

CLASS DEFINITION:

The lawsuit seeks to recover losses on behalf of Sana Biotechnology, Inc. investors who were adversely affected by alleged securities fraud between March 17, 2023 and November 4, 2024. Follow the link below to get more information and be contacted by a member of our team:

Sana Biotechnology Lawsuit Submission Form

SANA investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.

CASE DETAILS:

The filed complaint alleges that defendants made false statements and/or concealed that: (i) Sana was at significant risk of having insufficient funds to maintain its current operations and advance one or more of its product candidates; (ii) SC291 in oncology, SC379, and SG299 were less promising than defendants had led investors to believe; (iii) in order to preserve cash and advance its more promising product candidates, Sana was likely to decrease funding for and/or discontinue SC291 in oncology, SC379, and SG299, as well as significantly reduce its headcount; (iv) accordingly, defendants overstated Sana's financial capacity to maintain its current operations and advance its existing product candidates; and (v) as a result, defendants' public statements were materially false and/or misleading at all relevant times.

WHAT'S NEXT?

If you suffered a loss in Sana Biotechnology, Inc. during the relevant time frame, you have until May 20, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

NO COST TO YOU:

If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.

WHY LEVI & KORSINSKY:

Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

Related News